Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

医学 索拉非尼 甲状腺癌 内科学 安慰剂 实体瘤疗效评价标准 临床终点 肿瘤科 耐火材料(行星科学) 临床试验 癌症 甲状腺球蛋白 临床研究阶段 甲状腺 病理 肝细胞癌 替代医学 物理 天体生物学
作者
Marcia S. Brose,Christopher M. Nutting,Barbara Jarząb,Rossella Elisei,Salvatore Siena,Lars Bastholt,Christelle De La Fouchardière,Furio Pacini,Ralf Paschke,Young Kee Shong,Steven I. Sherman,Johannes W. A. Smit,John Chung,Christian Kappeler,Carol Peña,István Molnár,Martin Schlumberger
出处
期刊:The Lancet [Elsevier]
卷期号:384 (9940): 319-328 被引量:1378
标识
DOI:10.1016/s0140-6736(14)60421-9
摘要

Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer.In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (DECISION), we investigated sorafenib (400 mg orally twice daily) in patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within the past 14 months. Adult patients (≥18 years of age) with this type of cancer were enrolled from 77 centres in 18 countries. To be eligible for inclusion, participants had to have at least one measurable lesion by CT or MRI according to Response Evaluation Criteria In Solid Tumors (RECIST); Eastern Cooperative Oncology Group performance status 0-2; adequate bone marrow, liver, and renal function; and serum thyroid-stimulating hormone concentration lower than 0·5 mIU/L. An interactive voice response system was used to randomly allocate participants in a 1:1 ratio to either sorafenib or matching placebo. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoint was progression-free survival, assessed every 8 weeks by central independent review. Analysis was by intention to treat. Patients in the placebo group could cross over to open-label sorafenib upon disease progression. Archival tumour tissue was examined for BRAF and RAS mutations, and serum thyroglobulin was measured at baseline and at each visit. This study is registered with ClinicalTrials.gov, number NCT00984282, and with the EU Clinical Trials Register, number EudraCT 2009-012007-25.Patients were randomly allocated on a 1:1 basis to sorafenib or placebo. The intention-to-treat population comprised 417 patients (207 in the sorafenib group and 210 in the placebo group) and the safety population was 416 patients (207 in the sorafenib group and 209 in the placebo group). Median progression-free survival was significantly longer in the sorafenib group (10·8 months) than in the placebo group (5·8 months; hazard ratio [HR] 0·59, 95% CI 0·45-0·76; p<0·0001). Progression-free survival improved in all prespecified clinical and genetic biomarker subgroups, irrespective of mutation status. Adverse events occurred in 204 of 207 (98·6%) patients receiving sorafenib during the double-blind period and in 183 of 209 (87·6%) patients receiving placebo. Most adverse events were grade 1 or 2. The most frequent treatment-emergent adverse events in the sorafenib group were hand-foot skin reaction (76·3%), diarrhoea (68·6%), alopecia (67·1%), and rash or desquamation (50·2%).Sorafenib significantly improved progression-free survival compared with placebo in patients with progressive radioactive iodine-refractory differentiated thyroid cancer. Adverse events were consistent with the known safety profile of sorafenib. These results suggest that sorafenib is a new treatment option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer.Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals (an Amgen subsidiary).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海应助Kismet采纳,获得10
3秒前
3秒前
今后应助英勇的书包采纳,获得10
3秒前
8秒前
海藻酸发布了新的文献求助10
13秒前
14秒前
17秒前
汉堡包应助跳跃碧灵采纳,获得30
17秒前
李爱国应助SwapExisting采纳,获得10
19秒前
海藻酸完成签到,获得积分10
19秒前
麻薯头头发布了新的文献求助10
19秒前
cccyc发布了新的文献求助10
23秒前
是的地方公共单车完成签到,获得积分10
25秒前
留胡子的雨柏完成签到,获得积分20
26秒前
sigrid完成签到 ,获得积分10
27秒前
眯眯眼的山柳完成签到,获得积分20
29秒前
29秒前
34秒前
37秒前
37秒前
Leone发布了新的文献求助10
39秒前
tiger发布了新的文献求助10
44秒前
金轩完成签到 ,获得积分10
46秒前
Li关注了科研通微信公众号
47秒前
47秒前
万能图书馆应助cccyc采纳,获得10
49秒前
wtf发布了新的文献求助10
50秒前
Yvan完成签到,获得积分10
51秒前
53秒前
古蓦然完成签到,获得积分10
53秒前
53秒前
小young完成签到 ,获得积分10
54秒前
慕青应助加加油采纳,获得10
54秒前
misalia完成签到,获得积分10
55秒前
tiger完成签到,获得积分10
56秒前
59秒前
59秒前
宋十一发布了新的文献求助10
1分钟前
hiadg完成签到 ,获得积分10
1分钟前
小青新完成签到 ,获得积分10
1分钟前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137638
求助须知:如何正确求助?哪些是违规求助? 2788565
关于积分的说明 7787590
捐赠科研通 2444902
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601023